Dot1L-IN-4 是一种有效的类端粒沉默干扰体 1 (DOT1L) 抑制剂，IC50 SPA DOT1L 为 0.11 nM。
货号:ajcx34070
CAS:2565705-02-2
分子式:C28H27ClF2N8O5S
分子量：661.08
溶解度:DMSO : 250 mg/mL (378.17 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.11 nM[1].

Dot1L-IN-4 (Compound 10) is tested in cellular assays to assess the ability to inhibit the dimethylation of H3K79 in HeLa cells (ED50 H3K79me2 Elisa=1.7 nM) and HOXA9 gene expression in Molm-13 cells (ED50 HOXA9 RGA=33 nM). Dot1L-IN-4 also inhibits mixed lineage leukemia (MLL) with an IC50 of 99 µM[1].

Dot1L-IN-4 (Compound 10; 300 mg/kg; p.o.; qd) is not tolerated at such a high dose by tumor xenograft bearing mice, and at a 6-fold reduced dose, the tumor growth as well as the HOXA9 reporter gene mRNA are reduced only by less than half as compared to control animals[1].

[1]. FrÉdÉric Stauffer, et al. New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse. ACS Med. Chem. Lett. 2019, 10, 12, 1655-1660.